©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pathophysiol. May 12, 2020; 11(3): 43-56
Published online May 12, 2020. doi: 10.4291/wjgp.v11.i3.43
Published online May 12, 2020. doi: 10.4291/wjgp.v11.i3.43
Selective granulocyte and monocyte apheresis in inflammatory bowel disease: Its past, present and future
Xiu-Li Chen, Jing-Wei Mao, Ying-De Wang, Department of Gastroenterology, the First Affiliated Hospital of Dalian Medical University, Dalian 116011, Liaoning Province, China
Author contributions: Chen XL and Mao JW performed the literature review, wrote and edited the initial manuscript; Wang YD wrote and edited the final manuscript.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Corresponding author: Ying-De Wang, MD, Chief Physician, Professor, Department of Gastroenterology, the First Affiliated Hospital of Dalian Medical University, No. 222, Zhongshan Road, Xigang District, Dalian 116011, Liaoning Province, China. albertwyd@163.com
Received: December 31, 2019
Peer-review started: December 31, 2019
First decision: February 19, 2020
Revised: March 5, 2020
Accepted: April 8, 2020
Article in press: April 8, 2020
Published online: May 12, 2020
Processing time: 132 Days and 19.8 Hours
Peer-review started: December 31, 2019
First decision: February 19, 2020
Revised: March 5, 2020
Accepted: April 8, 2020
Article in press: April 8, 2020
Published online: May 12, 2020
Processing time: 132 Days and 19.8 Hours
Core Tip
Core tip: Conventional therapies for inflammatory bowel disease (IBD) patients including mesalazine, corticosteroids, and immunosuppressants have been used for decades with unsatisfactory outcomes due to ineffectiveness or side effects. Although the emerging biologic agents have revolutionized IBD treatment, severe opportunistic infections, primary or secondary loss of response, etc. are the major clinical concerns of clinicians and patients. In recent years, selective granulocyte and monocyte apheresis has been used in Japan, Europe, China and elsewhere for its advantages of satisfactory efficacy and high safety profile. Granulocyte and monocyte apheresis therapy is an important and promising therapeutic option for IBD patients.